Compare AFLAC Incorporated (AFL) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AFLAC Incorporated vs Xylem, Inc. — how do they compare? AFLAC Incorporated trades at $121.12 (market cap $60.70B), while Xylem, Inc. trades at $122.08 (market cap $28.76B). The key difference: AFLAC Incorporated is far larger — about 2.1× Xylem, Inc.'s market cap, and AFLAC Incorporated pays the higher dividend (2.02%). Which is the better fit depends on your goals.
| AFL | XYL | |
|---|---|---|
Market Cap | $60.70B | $28.76B |
Sector | Financials | Industrials |
52-Week High | $129.55 | $152.95 |
52-Week Low | $103.55 | $106.34 |
Enterprise Value | $70.65B | $30.54B |
Dividend Yield | 2.02% | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AFL trades at $121.94, down 2.14% with bearish technical signals and recent earnings misses. The stock shows strong profitability with 26.59% net margin and 16.91% ROE, but faces revenue declines from $19.1B in 2024 to $17.4B in 2025. Recent news highlights AFL's rebranding efforts and dividend consistency amid healthcare cost pressures. Technical indicators show oversold RSI at 17.69 with support at $117.
Outlook remains cautious with mixed analyst sentiment (28% buy, 56% hold) and $118 consensus target below current price. Risks include Japan market exposure and currency headwinds, balanced by 43-year dividend growth history and strong cash flow generation. The stock offers value at 13x P/E but requires monitoring of revenue stabilization.
Xylem (XYL) trades at $121.19, up 0.72% today, with a bullish technical trend and strong fundamental performance. The company reported Q2 2026 EPS of $1.46, beating estimates, and raised full-year profit guidance. Revenue growth is steady, with a net income margin of 11.15% in 2025. Recent acquisitions, like Cornell Pump and Roper Pump, aim to strengthen its industrial water technology presence. The stock shows bullish moving averages but a neutral RSI, with key resistance at $123.
Outlook remains positive due to earnings beats, margin expansion, and strategic acquisitions. Risks include execution of integration and macroeconomic pressures. Analyst consensus is a buy with a $150.43 price target, implying significant upside. Institutional activity is mixed, with some funds increasing stakes while others reduced holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the two largest insurance markets in the world, the U.S. and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accidents, disability, and long-term-care insurance. It markets its products through independent distributors, selling most of its policies directly to consumers at their places of work.
Read more on AFL →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
